中国报告大厅网讯,5月20日,中国生物制药企业迎来历史性时刻——三生制药与跨国药企巨头辉瑞达成一项总金额达60.5亿美元的合作协议。这一交易不仅刷新了国产双特异性抗体药物(双抗)海外授权的首付款纪录,更成为今年创新药出海浪潮中的标志性事件。随着中国创新药研发能力持续提升,本土药企正通过国际合作加速抢占全球市场,此次合作进一步印证了中国制药行业在国际生物医药领域的竞争力。 一、60.5亿美元重磅...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.